A new drug shows promise for hard-to-treat high blood pressure

Baxdrostat, a new aldosterone synthase inhibitor, shows promise for resistant hypertension in a recent clinical trial. The 12-week study of nearly 800 patients found those taking 1-2mg of baxdrostat with existing medications saw systolic pressure drop 9-10 mm Hg more than placebo groups, with 40% reaching healthy levels. Unlike current treatments, baxdrostat avoids side effects like breast tenderness or sexual dysfunction while providing sustained blood pressure reduction, potentially lowering risk of heart attack and stroke.